RBI 6000
Alternative Names: RBI-6000Latest Information Update: 28 Jul 2024
At a glance
- Originator Immunomic Therapeutics; Replicate Bioscience
- Class Antivirals; RNA
- Mechanism of Action Immunomodulators; Viral protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Human papillomavirus infections
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Human-papillomavirus-infections in USA
- 24 Jun 2020 Immunomic Therapeutics and Replicate Bioscience agree to co-develop therapeutics for Cancer, COVID-2019 infections, Human papillomavirus infections and Epstein-Barr virus infections